Game changers

3 health technologies developed in Houston that are changing the industry

Houston researchers are commercializing their organ 3D printing technology, a local hospital has a tiny medical device with a big impact, and more in health tech. Jordan Miller/Rice University

There's a huge opportunity for breakthrough medical technology in Houston thanks in large part to major universities, the Texas Medical Center, and other resources within health care startups.

From a new tiny implant that can deliver medicine into the patient remotely to printable human tissue, here are three health technologies coming out of Houston innovators to look out for.

Houston Methodist's tiny drug delivery implant

This tiny implant can have a big effect on patients. Courtesy of Houston Methodist

Houston Methodist nanomedicine researchers have developed an implant the size of a grape that can deliver medicine via a remote control. The device has applications in arthritis, diabetes, and heart disease treatment.

The battery-powered nanochannel deliver system uses Bluetooth technology and can dole out continuous, predetermined dosages for up to a year without refills. A proof-of-concept for the device published in Lab on a Chip.

"We see this universal drug implant as part of the future of health care innovation," says Alessandro Grattoni, chair of the nanomedicine department at Houston Methodist. "Some chronic disease drugs have the greatest benefit of delivery during overnight hours when it's inconvenient for patients to take oral medication. This device could vastly improve their disease management and prevent them from missing doses, simply with a medical professional overseeing their treatment remotely."

The devices can be programed for different dosage sizes and different release settings, which affect the voltage for the medicine delivery.

Houston Methodist has a number of new technologies it's introduced into its hospital system — click here to read about a few more.

NurseDash's resourceful scheduling tool

Houston-based NurseDash is the Uber of staffing nursing shifts in medical facilities. Photo via nursedash.com

Filling open nursing shifts has always been a challenge for hospitals and medical centers, and they've been forced to rely on outsourced companies to coordinate nurses to fill the shifts. NurseDash puts the power back in the hands of freelance nurses and the medical institutions that want to hire them.

Andy Chen, former CFO for Nobilis Health Corporation and co-founder of NurseDash, says the standard practice is hiring these agencies to fill shifts, and, while they promise to send someone, they don't even know who they'll be sending for a shift just hours away. This antiquated system prioritizes who comes in first, rather than a nurse's specialties or qualifications.

Since its debut, NurseDash, which is based in Houston's Galleria Area, has attracted 40 facilities in Houston, including hospitals, surgery centers, and senior living, and about 400 nurses. Chen says he isn't sure just what to call his technology yet, but compares it to the ride hailing of Uber or Lyft and calls it "a virtual bulletin board."

The company has already expanded beyond Houston to northeast Ohio, which the founders say has a similar competitive dynamic to the Houston market. The next goal is to hit the rest of the top 10 largest cities in the United States. To read more about the app and startup, click here.

Volumetric's human tissue-printing technology

Rice University bioengineer Daniel Sazer prepares a scale-model of a lung-mimicking air sac for testing. Jeff Fitlow/Rice University

In a world where organ transplants means an incredible amount of time, money, and patience, there might soon be another option on the operating table. Volumetric is a startup that came out of a human tissue-printing technology developed at Rice University.

Jordan Millar developed the 3D printer in his lab at Rice, and still has ongoing research within the technologies. However, Miller says he very strategically chose to launch a for-profit company in 2018 — mainly, to provide access.

"If we want to do translational research, commercialization is important," reasons Miller. "We need to build the market to get that technology into the world."

Right now, the device is printing scaled down organs, and a contraption that looks a bit like a futuristic beehive, graced the cover of the May 3 issue of the journal Science. It's a working air sac complete with blood vessels, the beginnings of a technology that is perhaps only a decade from being implanted in humans. To read more about Volumetric, click here.


Trending News

Building Houston

 
 

A Rice research team is tapping into materials science to better understand Alzheimer’s disease, a UH professor is developing a treatment for hereditary vision loss, and a BCM researcher is looking at stress and brain cancer. Photo by Gustavo Raskosky/Rice University

Research, perhaps now more than ever, is crucial to expanding and growing innovation in Houston — and it's happening across the city right under our noses.

In InnovationMap's latest roundup of research news, three Houston institutions are working on life-saving health care research thanks to new technologies.

Rice University scientists' groundbreaking alzheimer's study

Angel Martí (right) and his co-authors (from left) Utana Umezaki and Zhi Mei Sonia He have published their latest findings on Alzheimer’s disease. Photo by Gustavo Raskosky/Rice University

According to the Centers for Disease Control and Prevention, Alzheimer’s disease will affect nearly 14 million people in the U.S. by 2060. A group of scientists from Rice University are looking into a peptide associated with the disease, and their study was published in Chemical Science.

Angel Martí — a professor of chemistry, bioengineering, and materials science and nanoengineering and faculty director of the Rice Emerging Scholars Program — and his team have developed a new approach using time-resolved spectroscopy and computational chemistry, according to a news release from Rice. The scientists "found experimental evidence of an alternative binding site on amyloid-beta aggregates, opening the door to the development of new therapies for Alzheimer’s and other diseases associated with amyloid deposits."

Amyloid plaque deposits in the brain are a main feature of Alzheimer’s, per Rice.

“Amyloid-beta is a peptide that aggregates in the brains of people that suffer from Alzheimer’s disease, forming these supramolecular nanoscale fibers, or fibrils” says Martí in the release. “Once they grow sufficiently, these fibrils precipitate and form what we call amyloid plaques.

“Understanding how molecules in general bind to amyloid-beta is particularly important not only for developing drugs that will bind with better affinity to its aggregates, but also for figuring out who the other players are that contribute to cerebral tissue toxicity,” he adds.

The National Science Foundation and the family of the late Professor Donald DuPré, a Houston-born Rice alumnus and former professor of chemistry at the University of Louisville, supported the research, which is explained more thoroughly on Rice's website.

University of Houston professor granted $1.6M for gene therapy treatment for rare eye disease

Muna Naash, a professor at UH, is hoping her research can result in treatment for a rare genetic disease that causes vision loss. Photo via UH.edu

A University of Houston researcher is working on a way to restore sight to those suffering from a rare genetic eye disease.

Muna Naash, the John S. Dunn Endowed Professor of biomedical engineering at UH, is expanding a method of gene therapy to potentially treat vision loss in patients with Usher Syndrome Type 2A, or USH2A, a rare genetic disease.

Naash has received a $1.6 million grant from the National Eye Institute to support her work. Mutations of the USH2A gene can include hearing loss from birth and progressive loss of vision, according to a news release from UH. Naash's work is looking at applying gene therapy — the introduction of a normal gene into cells to correct genetic disorders — to treat this genetic disease. There is not currently another treatment for USH2A.

“Our goal is to advance our current intravitreal gene therapy platform consisting of DNA nanoparticles/hyaluronic acid nanospheres to deliver large genes in order to develop safe and effective therapies for visual loss in Usher Syndrome Type 2A,” says Naash. “Developing an effective treatment for USH2A has been challenging due to its large coding sequence (15.8 kb) that has precluded its delivery using standard approaches and the presence of multiple isoforms with functions that are not fully understood."

BCM researcher on the impact of stress

This Baylor researcher is looking at the relationship between stress and brain cancer thanks to a new grant. Photo via Andriy Onufriyenko/Getty Images

Stress can impact the human body in a number of ways — from high blood pressure to hair loss — but one Houston scientist is looking into what happens to bodies in the long term, from age-related neurodegeneration to cancer.

Dr. Steven Boeynaems is assistant professor of molecular and human genetics at Baylor College of Medicine. His lab is located at the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and he also is a part of the Therapeutic Innovation Center, the Center for Alzheimer’s and Neurodegenerative Diseases, and the Dan L Duncan Comprehensive Cancer Center at Baylor.

Recently, the Cancer Prevention and Research Institute of Texas, or CPRIT, awarded Boeynaems a grant to continue his work studying how cells and organisms respond to stress.

“Any cell, in nature or in our bodies, during its existence, will have to deal with some conditions that deviate from its ideal environment,” Boeynaems says in a BCM press release. “The key issue that all cells face in such conditions is that they can no longer properly fold their proteins, and that leads to the abnormal clumping of proteins into aggregates. We have seen such aggregates occur in many species and under a variety of stress-related conditions, whether it is in a plant dealing with drought or in a human patient with aging-related Alzheimer’s disease."

Now, thanks to the CPRIT funding, he says his lab will now also venture into studying the role of cellular stress in brain cancer.

“A tumor is a very stressful environment for cells, and cancer cells need to continuously adapt to this stress to survive and/or metastasize,” he says in the release.

“Moreover, the same principles of toxic protein aggregation and protection through protein droplets seem to be at play here as well,” he continues. “We have studied protein droplets not only in humans but also in stress-tolerant organisms such as plants and bacteria for years now. We propose to build and leverage on that knowledge to come up with innovative new treatments for cancer patients.”

Trending News